Form 8-K - Current report:
SEC Accession No. 0001599298-25-000038
Filing Date
2025-01-24
Accepted
2025-01-24 16:23:52
Documents
14
Period of Report
2025-01-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20250122.htm   iXBRL 8-K 28680
  Complete submission text file 0001599298-25-000038.txt   184104

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20250122.xsd EX-101.SCH 2042
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20250122_def.xml EX-101.DEF 14787
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20250122_lab.xml EX-101.LAB 26043
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20250122_pre.xml EX-101.PRE 15429
16 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20250122_htm.xml XML 3344
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 25554513
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)